[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Contrast Induced Nephropathy pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 35 pages | ID: CE53F14BC6D6EN

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Contrast Induced Nephropathy PIPELINE HIGHLIGHTS
Contrast Induced Nephropathy is one of the widely researched conditions during 2020 with 3 companies actively focusing on realizing pipeline’s potential. Development of Contrast Induced Nephropathy medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Contrast Induced Nephropathy market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Contrast Induced Nephropathy.

Good progress is anticipated during 2020 and 2021 with Contrast Induced Nephropathy pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Contrast Induced Nephropathy pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
The “Contrast Induced Nephropathy pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Contrast Induced Nephropathy pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Contrast Induced Nephropathy presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Contrast Induced Nephropathy pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Contrast Induced Nephropathy DRUG PROFILES
Contrast Induced Nephropathy development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Contrast Induced Nephropathy COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Contrast Induced Nephropathy drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Contrast Induced Nephropathy. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 3 Contrast Induced Nephropathy companies including company overview, key snapshot, contact information, and their strategies on accelerating Contrast Induced Nephropathy pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Pharming Group NV, Radikal Therapeutics Inc, Saghmos Therapeutics Inc

  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Contrast Induced Nephropathy
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners

1.1 Contrast Induced Nephropathy- Disease overview
1.2 Contrast Induced Nephropathy- Market Size
1.3 Contrast Induced Nephropathy- Companies Involved


2.1 Contrast Induced Nephropathy Pipeline by Phase
2.2 Contrast Induced Nephropathy Pipeline by Mechanism of Action
2.3 Contrast Induced Nephropathy Pipeline by Route of Administration
2.4 Contrast Induced Nephropathy Pipeline- New Molecular Entities
2.5 Contrast Induced Nephropathy Pipeline- Orphan Drug Designation/ Special Designation


3.1 Current Status
3.2 Contrast Induced Nephropathy Drug Snapshot
3.3 Contrast Induced Nephropathy Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Pharming Group NV Contrast Induced Nephropathy Pipeline Insights and Clinical Trials
4.2 Radikal Therapeutics Inc Contrast Induced Nephropathy Pipeline Insights and Clinical Trials
4.3 Saghmos Therapeutics Inc Contrast Induced Nephropathy Pipeline Insights and Clinical Trials



6.1 Sources and Methodology
6.2 Contact Information

More Publications